Tularik & Amgen: A Model of Business Development (and Good News for Biotech, Too)

Things have been bleak on the discovery side of the dealmaking world, as evidenced by a paucity of Big Pharma alliances. But the Tularik/Amgen transaction indicates a renewed interest in target-stage transactions, though with the best prospects reserved for cancer focused companies with significant chemistry capabilities.